Hydrolysis of surfactant-associated phosphatidylcholine by mammalian secretory phospholipases A2

R. Duncan Hite1, Michael C. Seeds1, Randy B. Jacinto1, R. Balasubramanian1, Moseley Waite2, and David Bass1

1 Section on Pulmonary and Critical Care, Department of Internal Medicine, and 2 Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Hydrolysis of surfactant-associated phospholipids by secretory phospholipases A2 is an important potential mechanism for surfactant dysfunction in inflammatory lung diseases. In these conditions, airway secretory phospholipase A2 (sPLA2) activity is increased, but the type of sPLA2 and its impact on surfactant function are not well understood. We examined in vitro the effect of multiple secretory phospholipases A2 on surfactant, including their ability to 1) release free fatty acids, 2) release lysophospholipids, and 3) increase the minimum surface tension (gamma min) on a pulsating bubble surfactometer. Natural porcine surfactant and Survanta were exposed to mammalian group I (recombinant porcine pancreatic) and group II (recombinant human) secretory phospholipases A2. Our results demonstrate that mammalian group I sPLA2 hydrolyzes phosphatidylcholine (PC), producing free fatty acids and lysophosphatidylcholine, and increases gamma min. In contrast, mammalian group II sPLA2 demonstrates limited hydrolysis of PC and does not increase gamma min. Group I and group II secretory phospholipases A2 from snake venom hydrolyze PC and inhibit surfactant function. In summary, mammalian secretory phospholipases A2 from groups I and II differ significantly from each other and from snake venom in their ability to hydrolyze surfactant-associated PC.

lysophospholipid; lung injury; asthma; pulsating bubble surfactometer

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

SURFACTANT is a complex mixture of phospholipids (80-90% wt/wt), neutral lipids (5-10%), and proteins (5-10%) that lines the alveolar surface in a monomolecular film and principally serves to reduce the work of breathing by lowering the surface tension of the alveolus and distal conducting airways (12). Synthesis, secretion, and reuptake of surfactant is controlled primarily by alveolar type II epithelial cells. Phosphatidylcholine (PC) is the most abundant phospholipid (80%), and the fatty acid acyl composition of PC is predominantly saturated palmitic acid (65%). The surfactant-associated apoproteins [surfactant protein (SP) A-D] markedly enhance the adsorption, spreading, and maintenance of the phospholipid monolayer (27, 44).

Disease states that result in a deficiency of surfactant are characterized by severe dysfunction of the lungs, including reduced gas exchange, decreased lung compliance, and increased airway resistance. Premature infants with insufficient surfactant synthesis by type II epithelial cells develop respiratory distress syndrome (RDS) (32). Children and adults can also develop an acute RDS (ARDS) that is similar to RDS but is the result of a severe systemic inflammatory insult (16, 19). Similarly, in asthma, the function of surfactant to maintain the patency of conducting airways is inhibited by inflammation (21, 29). Several mechanisms for inflammation-mediated inhibition of surfactant have been suggested, including 1) direct surfactant injury by hydrolytic enzymes, proteases, and metabolic by-products, 2) disruption of the surfactant monolayer by serum proteins that leak into the alveolus, and 3) reduction in surfactant synthesis by direct injury to type II epithelial cells (28).

One specific mechanism for surfactant injury is hydrolysis of surfactant-associated phospholipids by phospholipases A2 (22, 25). Intratracheal administration of phospholipases A2 to adult rats results in severe lung injury and serves as an in vitro model of ARDS (13). Phospholipases A2 have been categorized into at least 10 groups (I-X) based on amino acid sequence data (10, 11). Many of these enzymes are secreted extracellularly and are commonly referred to as secretory phospholipases A2. The secretory phospholipases A2 share many important characteristics including 1) small size (13-18 kDa), 2) stability in acidic pH, 3) millimolar calcium requirement for activity, and 4) minimal preference for any specific fatty acid in the sn-2 position of the phospholipid. The secretory phospholipase A2 (sPLA2) groups are differentiated by their structural configuration, including amino acid sequence and the number and location of disulfide bonds. However, the biological activity of the enzymes between groups can differ significantly as subtle differences in the sequences regulate interfacial substrate binding and catalysis (41).

The first mammalian sPLA2 (group I) has been isolated and purified from porcine, bovine, equine, and human pancreas, with 75-80% homology of the amino acid sequences between the species (39). Although the principal role of the pancreatic sPLA2 is in digestion, the protein and mRNA for human group I sPLA2 are also present in human lung (35). The mammalian group I sPLA2 preferentially hydrolyzes PC and can hydrolyze surfactants in vitro (22, 37). Mammalian group II sPLA2 was initially isolated and purified from inflamed peritoneal and synovial fluids (6, 20). Expression of group II sPLA2 has been demonstrated in several inflamed and noninflamed tissues, including the lung (25). The principal roles of the group II sPLA2 are believed to be in host defense through potent antibacterial effects and in inflammation through signal transduction and generation of arachidonic acid metabolites (36, 42). The group II secretory phospholipases A2 prefer phosphatidylethanolamine and phosphatidylserine and hydrolyze PC less efficiently than group I sPLA2 (6, 20). New mammalian low-molecular-weight phospholipases A2 have been identified, groups V and X, but their principal roles are not fully understood (1, 10).

The bronchoalveolar lavage (BAL) fluid (BALF) from humans with ARDS contains less total phospholipid (including PC and phosphatidylglycerol), higher amounts of lysophosphatidylcholine (lysoPC), and increased sPLA2 activity (16). Similarly, BALF from asthmatic patients who are challenged with endobronchial antigen instillation demonstrates increased amounts of sPLA2 activity and 1-palmitoyl-lysoPC (5, 7). In combination, the BALF characteristics of patients with ARDS and asthma strongly support the presence of secretory phospholipases A2. The group and cellular origins of the secretory phospholipases A2 responsible for the changes in phospholipid composition are unknown. Examination of BALF from ARDS patients with antibodies to group II and heparin affinity confirms the presence of a group II sPLA2 and a second, non-group II sPLA2 (25). Furthermore, the proenzyme of group I sPLA2 is present in the serum of patients with ARDS (30).

In this study, we examined the capacity of the mammalian group I (pancreatic) and group II (inflammation) enzymes to 1) release free fatty acids, 2) increase the formation of lysophospholipids, and 3) cause surfactant dysfunction. Our results identify significant differences in the hydrolysis of surfactant-associated PC by these enzymes and provide important information in understanding the role of sPLA2-mediated hydrolysis of surfactant in inflammatory lung diseases.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Phospholipid and lysophospholipid standards were purchased from Avanti Polar Lipids (Alabaster, AL). Arachidonic acid was purchased from Cayman Chemical (Ann Arbor, MI). The 17:0 fatty acid standard was purchased from NuPrep (Elysian, MN). Radiolabeled [2-palmitoyl-9,10-3H(N)]dipalmitoyl-L-alpha -phosphatidylcholine ([3H]DPPC) was purchased from DuPont NEN (Boston, MA). COS-1 cells were obtained from the American Type Culture Collection (Manassas, VA). All solvents were purchased from Fisher Scientific (Pittsburgh, PA). Diethylaminoethyl dextran was purchased from Pharmacia (Piscataway, NJ). All additional chemicals were purchased from Sigma (St. Louis, MO), including the following phospholipases: recombinant porcine pancreas (group I), Naja naja (snake venom group I), and Crotalus atrox (snake venom group II).

Surfactants. Natural porcine surfactant (NPS) was isolated from juvenile pigs (10-15 kg) that were euthanized with intravenous Pentothal Sodium. Repetitive saline lavage (60-80 ml/kg) was performed via an endotracheal tube. Within 30 min, cells were centrifuged (600 g for 30 min) from the lavage fluid. A surfactant pellet was isolated from the cell-free supernatant by ultracentrifugation (15,000 g for 60 min). The pellet was resuspended in saline and washed three times with normal saline and repeat ultracentrifugation. After the surfactant pellet was washed, it was resuspended in saline and the phosphorus content was determined with the method of Bartlett (2). The surfactant suspension was separated into aliquots, which were stored at -70°C. Survanta (Ross Laboratories, St. Louis, MO) samples were stored at 0-5°C. Individual aliquots of the surfactants were thawed on the day of each experiment.

Preparation of human group II phospholipases. Recombinant human group II (rhGpII) sPLA2 was obtained by transfecting COS-1 cells with a pCMV-5 plasmid containing an sPLA2 gene construct with the method of Wong et al. (43). rhGpII sPLA2 was collected after 3 days of transfection and partially purified by overnight extraction in 0.18 M H2SO4. A second example of group II sPLA2 was obtained by partial purification of human synovial fluid (HuSF) from the inflamed joints of patients with rheumatoid arthritis by acid extraction. All acid extracts were dialyzed against a buffer (pH = 7.40) containing 0.05 M Tris and 0.05 M NaCl and stored as aliquots at -70°C. Aliquots were thawed and used fresh daily for each experiment. The protein content of the rhGpII and HuSF sPLA2 was measured with Bradford's Coomassie blue reagent (Pierce, Rockford, IL).

Distribution of [3H]DPPC in surfactant. A stock solution of labeled surfactant was prepared fresh daily. Aliquots of [3H]DPPC (10 µCi/ml in 1:1 toluene-ethanol, 0.1 µCi/incubation) were transferred to microcentrifuge tubes and dried under N2 gas. NPS or Survanta was added and diluted to 1.0 mg phospholipid/ml in saline buffered (pH = 7.4) with Tris (5.0 mM) and CaCl2 (5.0 mM) and mixed three times with a Branson sonicator (Heat Systems-Ultrasonics, Farmingdale, NY) with a stepped microtip set at ~40 W for 15 s. Sonicated samples were loaded at the bottom of a discontinuous sucrose gradient (in H2O): 0 M (3 ml), 0.25 M (11 ml), 0.35 M (11 ml), and 0.60 M (11 ml including sample). The gradient was ultracentrifuged (64,000 g for 60 min at 4°C), and fractions were removed and analyzed for radioactivity and phosphorus. Data are expressed as the percentage of total radioactivity and the absolute phosphorus (in nmol) in each fraction.

Hydrolysis of [3H]oleate-labeled Escherichia coli. [3H]oleate-labeled E. coli was prepared with a modification of the method of Kramer and Pepinsky (26). Labeled E. coli (400 pmol lipid/sample, 0.1 µCi/ml) was then exposed to secretory phospholipases A2 for 1 h at 37°C. The incubation was terminated by lipid extraction of the phospholipids and fatty acids with the method of Bligh and Dyer (4). The phospholipids and fatty acids were separated by thin-layer chromatography (TLC) with Silica G plates (Analtech, Newark, DE) and a mobile solvent phase of hexane, ethyl ether, and formic acid (90:60:6 by vol). Phospholipid and free fatty acid fractions were visualized on the TLC plates with I2 vapor and scraped and analyzed for radioactivity with a scintillation counter. Before TLC, each sample was supplemented with unlabeled arachidonic acid (40 µg) to enhance free fatty acid staining by the I2 vapor. The data are expressed as the percentage of the total radioactivity recovered in the free fatty acid fraction.

Hydrolysis of [3H]DPPC-labeled surfactant. Aliquots (200 µl) of the sonicated, [3H]DPPC-labeled surfactant stock were diluted to a final phospholipid concentration of 0.5 mg/ml with saline containing 5 mM Tris (pH 7.4) and 5 mM CaCl2 and incubated in the presence or absence of secretory phospholipases A2 for 2 h at 37°C. Samples were then processed and analyzed as outlined in Hydrolysis of [3H]oleate-labeled Escherichia coli.

Surfactant function. Aliquots (40 µl) of the surfactant-sPLA2 reaction mixtures were transferred into sample chambers designed for the pulsating bubble surfactometer (14). The biophysical ability to lower the surface tension of each sample (40 µl) was analyzed at 37°C with the pulsating bubble surfactometer. A bubble was formed in the aqueous sample chamber, and pressure at the air-liquid interface was continuously transduced during repeated expansion and contraction (20 cycles/min) of the bubble between a minimum radius (r) of 0.40 mm and a maximum r of 0.55 mm. Surface tension (gamma ) was continuously calculated with the LaPlace equation (P = 2pi /r). Pulsations were continued for a maximum of 10 min or until gamma  <=  1.0 mN/m for at least 3 min. The minimum surface tension (gamma min) is defined as the average of the lowest surface tension measurement from each minute over three consecutive minutes during the entire 10-min analysis.

Phospholipid and free fatty acid composition. Surfactant samples were prepared and incubated in the presence or absence of sPLA2 as described. After lipid extraction, specific phospholipid fractions were isolated by the TLC method of Fine and Sprecher (15) by comparison to phospholipid standards. Fractions were identified with the use of I2 and scraped and analyzed for phosphorus content. The data are expressed as the percentage of total phospholipid recovered. Free fatty acid fractions were scraped and esterified with the method of Rogozinski (33). The esterified samples were separated with gas chromatography (Hewlett-Packard 5890) with a bonded silica DB225 column (Alltech, Avondale, PA) and quantified with flame ionization detection and comparison to a 17:0 internal standard.

Statistics. Data are the means ± SD of at least three experiments. Statistical significance was determined by Student's t-test.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

A model was established for measuring hydrolysis of surfactant phospholipids by secretory phospholipases A2. A trace amount of [3H]DPPC was mixed with surfactant by sonication as described in MATERIALS AND METHODS such that after exposure of the mixture to an sPLA2, the release of the [3H]palmitate from the sn-2 position of the surfactant phospholipid could be quantitated by TLC analysis of the free fatty acids. To confirm that the [3H]DPPC was homogeneously mixed into the surfactant, the mixture was fractionated over sucrose density gradients, and the colocalization of lipid phosphorus and [3H]DPPC was established (Fig. 1). Free [3H]DPPC in the absence of surfactant migrated in the early gradient fractions (fractions 1-3). However, [3H]DPPC comigrated with the major surfactant phospholipid peak (fractions 5-10) when the two were mixed by sonication before gradient separation. Thus trace-labeled surfactant appears to be a uniformly mixed substrate.


View larger version (26K):
[in this window]
[in a new window]
 


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 1.   Incorporation of [2-palmitoyl-9,10-3H(N)]dipalmitoyl-L-alpha -phosphatidylcholine ([3H]DPPC) in natural porcine surfactant (NPS). NPS was mixed and sonicated with 10 µCi/ml of [3H]DPPC. Samples were loaded at bottom of a discontinuous sucrose gradient. Data are means ± SD.

Labeled surfactant was then subjected to hydrolysis by sPLA2. Porcine pancreatic sPLA2, a group I enzyme, readily hydrolyzed the labeled E. coli and surfactant in a dose-dependent manner (Fig. 2). Hydrolysis increased over the range of 10-1,000 U/ml of enzyme. To compare the ability of the various secretory phospholipases A2 to hydrolyze surfactant-associated phospholipids, we performed E. coli hydrolysis experiments. The hydrolysis of E. coli serves as the standard for comparison. In all experiments, we defined one unit of enzyme activity as the amount required to result in 50% of the maximum E. coli hydrolysis. The group I sPLA2 also demonstrated significant hydrolysis of the labeled E. coli.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 2.   Porcine pancreatic group I secretory phospholipase A2 (sPLA2) hydrolysis of [3H]DPPC-labeled surfactant and [3H]oleate-labeled Escherichia coli. Porcine pancreatic sPLA2 was incubated at 37°C with either [3H]DPPC-labeled surfactant (0.5 mg of phospholipid/ml) for 2 h or [3H]oleate-labeled E. coli (10 µg of phospholipid/ml) for 1 h. Concentration of porcine pancreatic sPLA2 ([Porcine sPLA2]) is expressed in U/ml where 1 unit is equivalent to amount of enzyme required to achieve 50% of maximum E. coli hydrolysis. Phospholipids and fatty acids were separated with thin-layer chromatography (TLC). Data are means ± SD of %total radioactivity in each free fatty acid fraction. * P <=  0.02 compared with control without group I sPLA2 (data not shown).

rhGpII sPLA2 was examined for its ability to hydrolyze surfactant phospholipids. The recombinant protein expressed in COS-1 cells demonstrated significant hydrolysis of [3H]oleate-labeled E. coli (Fig. 3) but demonstrated only minimal hydrolysis of [3H]DPPC-labeled surfactant despite use of concentrations of up to 10,000 U/ml. In these experiments, we again defined one unit of enzyme activity as the amount required to result in 50% of the maximum E. coli hydrolysis. These results suggest that the mammalian group II sPLA2 is significantly less able to hydrolyze [3H]DPPC than the group I sPLA2. We considered the possibility that the rhGpII sPLA2 expressed by the COS-1 cells might be an incomplete or altered product and therefore might artificially demonstrate lower rates of surfactant hydrolysis than the native enzyme. To investigate that possibility, we performed identical experiments with the use of HuSF sPLA2 obtained from inflamed synovial fluid, and the rates of hydrolysis by HuSF for both substrates, [3H]DPPC-labeled surfactant and E. coli, were identical to the rates of hydrolysis with the rhGpII sPLA2 (data not shown). Despite the use of higher concentrations than were used for the group I porcine pancreas sPLA2, the hydrolysis of surfactant by both group II enzymes was minimal. To examine the effects of inhibitors (i.e., Clara cell protein) (23), which might potentially be present in our NPS preparations, we studied the activity of both group II enzymes against [3H]DPPC-labeled Survanta. The rates of hydrolysis in the Survanta preparations were identical to those in the labeled NPS preparations (data not shown).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 3.   Recombinant human group II (rhGpII) sPLA2 hydrolysis of [3H]DPPC-labeled surfactant and [3H]oleate-labeled E. coli. rhGpII sPLA2 was incubated at 37°C with either [3H]DPPC-labeled surfactant (0.5 mg phospholipid/ml) for 2 h or [3H]oleate-labeled E. coli (10 µg phospholipid/ml) for 1 h. Concentration of rhGpII sPLA2 ([rhGpII sPLA2]) is expressed in U/ml where 1 unit is equivalent to amount of enzyme required to achieve 50% of maximum E. coli hydrolysis. Phospholipids and fatty acids were separated with TLC. Data are means ± SD of %total radioactivity in each free fatty acid fraction. Significant difference compared with control without rhGpII sPLA2 (data not shown): * P < 0.01; dagger  P < 0.05.

The hydrolysis of surfactant phospholipids by secretory phospholipases A2 results in the production of a lysophospholipid and a free fatty acid. Consequently, the group I porcine pancreatic sPLA2 resulted in an increase in the lysoPC content and a decrease in the PC content (Fig. 4) over the same range as our [3H]DPPC-labeled surfactant experiments. The formation of lysoPC after exposure of surfactant to the maximum concentration of rhGpII sPLA2 (10,000 U/ml) was low and comparable to the levels of [3H]palmitate released as demonstrated in Fig. 3 (data not shown).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 4.   Alterations in surfactant phospholipids by porcine pancreatic group I sPLA2. NPS (0.5 mg of phospholipid/ml) was incubated in presence and absence of porcine pancreatic sPLA2 (0-1,000 U/ml) at 37°C for 2 h. Phospholipids were extracted and isolated with TLC, and each fraction was analyzed for phosphorus content. Data are means ± SD of %total phosphorus in phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) fractions. * P <=  0.001 compared with control without group I sPLA2.

The profile of fatty acids released from surfactant was also directly determined after hydrolysis of unlabeled surfactant with the porcine pancreatic group I sPLA2 (1,000 U/ml). As expected, palmitic acid was the predominant free fatty acid released, accounting for ~59% of the total (Fig. 5). In addition, a broad profile of released free fatty acids was seen, including myristic (14:0), palmitoleic (16:1), oleic (18:1), and linoleic (18:2). This profile of fatty acids released after hydrolysis of our juvenile NPS is comparable to the relative percentages estimated for the fatty acid compositions in the sn-2 position reported for calf surfactant PC (24). However, small differences between our NPS and calf PC do exist, including a smaller 16:1 fraction and a larger 18:2 fraction. These differences likely reflect differences in the composition of PC between the two species, and sn-2 fatty acids are released as a result of hydrolysis of other non-PC phospholipids (i.e., phosphatidylglycerol and phosphatidylethanolamine). A similar but smaller release of palmitic acid (P = 0.13) was seen in experiments in which the maximum concentration of rhGpII sPLA2 (10,000 U/ml) was used. This result is consistent with the lack of specificity for individual fatty acids in the sn-2 position typically demonstrated by group I and group II sPLA2, which contrasts with the preference of the high-molecular-weight cytosolic PLA2 for arachidonic acid (8).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 5.   Fatty acids released from surfactant phospholipids by porcine pancreatic group I sPLA2. NPS (0.5 mg of phospholipid/ml) was incubated in presence and absence of porcine pancreatic sPLA2 at 37°C for 2 h. Free fatty acids were separated with TLC, HCl methylated, extracted, and measured with gas chromatography with an internal standard. Data are means ± SD of concentrations of each fatty acid. * P <=  0.01 compared with control without group I sPLA2.

The impact of sPLA2-mediated hydrolysis of PC on surfactant function is demonstrated in Fig. 6. Increase in concentrations of the group I porcine pancreatic enzyme (100-1,000 U/ml) results in an increase in the gamma min, which reflects a decline in surfactant function. Although the hydrolysis of PC increases steadily over this dose range, the change in gamma  does not. Despite a further increase in hydrolysis between 500 and 1,000 U/ml, gamma min does not increase further and appears to reach a plateau. This result suggests that the relationship between hydrolysis of PC and surfactant function may depend on a critical "threshold" of degradation that limits optimal packing of the phospholipid monolayer at the air-liquid interface of the bubble. In contrast, exposure of labeled NPS to the maximum concentration of rhGpII sPLA2 (10,000 U/ml) did not result in an increase in gamma min (data not shown).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 6.   Comparison of porcine group I sPLA2-mediated hydrolysis and inhibition of surfactant function. [3H]DPPC-labeled surfactant (0.5 mg of phospholipid/ml) was incubated with porcine pancreatic sPLA2 (0-1,000 U/ml) at 37°C for 2 h in buffered saline with CaCl2 (5 mM). Data are means ± SD of minimum surface tensions recorded over 10 min on a pulsating bubble surfactometer and of %total radioactivity in free fatty acid fraction. Significant difference compared with control without group I sPLA2: * P < 0.001; dagger  P < 0.02.

To further compare the activity of secretory phospholipases A2 within and between groups I and II, we studied the ability of snake venom secretory phospholipases A2 to cause surfactant dysfunction (Fig. 7). In hydrolysis experiments, both of the snake venom secretory phospholipases A2, N. naja (group I) and C. atrox (group II), readily hydrolyze E. coli and labeled NPS, with activity for the [3H]DPPC-labeled NPS similar to that with the porcine pancreatic sPLA2 based on the comparable hydrolytic rates of E. coli (data not shown). Similarly, both snake venom secretory phospholipases A2, N. naja (100 U/ml) and C. atrox (100 U/ml), result in significant increases in gamma min. The ability of the mammalian and snake venom group I enzymes to cause surfactant dysfunction is remarkably similar. In contrast, the group II snake venom causes surfactant dysfunction, whereas the rhGpII sPLA2 does not.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 7.   Comparison of mammalian and snake venom sPLA2. NPS (0.5 mg phospholipid/ml) was incubated at 37°C for 2 h in buffered saline with CaCl2 (5 mM) with the following sPLA2: group I [porcine pancreatic (100 U/ml) and Naja naja (N. naja; 100 U/ml)] and group II [rhGpII (10,000 U/ml) and Crotalus atrox (C. atrox; 100 U/ml)]. Samples were then analyzed for function with pulsating bubble surfactometer. Data are means ± SD. * P < 0.001 compared with control without sPLA2.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Our data support the hypothesis that secretory phospholipases A2 may play a critical role in inflammatory lung diseases like ARDS and asthma. The most abundant surfactant-associated phospholipid, PC, is hydrolyzed by the mammalian group I sPLA2 (Fig. 2). This interaction results in the formation of lysoPC (Fig. 4) and free fatty acids (Fig. 5) and results in decreasing overall surfactant function (Fig. 6). The mammalian group II sPLA2 hydrolyzes surfactant-associated PC but with significantly less activity than the group I sPLA2 and does not increase gamma min. This difference in the mammalian enzymes is not solely explained by the class differences between group I and group II enzymes because the snake venom group II C. atrox resulted in significant PC hydrolysis and caused surfactant dysfunction.

Surprisingly, the group II sPLA2 rhGpII did not demonstrate significant hydrolysis of PC. The literature suggests that the group II enzyme would be the most likely candidate enzyme because of its release by phagocytes, including neutrophils and alveolar macrophages, in inflammatory states (3, 40). The increased levels of sPLA2 activity in patients with septic shock have been attributed to the release of group II enzymes (17). In addition, a BAL study (25) of patients with ARDS demonstrates an increase in the activity of sPLA2, which coelutes with purified group II standards on heparin column fractionation (25). However, this same BAL study also demonstrated an additional heparin column fraction, with significant sPLA2 activity from an unclear group or source. From our data, the second sPLA2 could be group I because its affinity for PC is substantially greater than that of the group II sPLA2 based on the relative activity for each enzyme toward E. coli as a substrate. The role for group I enzymes is supported by the propensity for ARDS in patients with pancreatitis and by models of pancreatitis where high levels of serum sPLA2 activity have been demonstrated (34). Although pancreatitis is an uncommon cause of ARDS and the pancreas is an unlikely source for increased sPLA2 activity in patients with asthma or in the majority of ARDS patients, there are additional sources of group I sPLA2. Expression of group I sPLA2 mRNA has been reported from nonpancreatic tissues including the human lung, and activated human granulocytes release the group I proenzyme (31, 35). Our data favor the group I sPLA2 as a more likely candidate enzyme than the group II sPLA2 for causing surfactant damage in ARDS and asthma.

In addition, recently identified secretory phospholipases A2 might also contribute to surfactant damage. A group V enzyme has been identified from a human cDNA library; it may be present in lung and appears to have a greater affinity for hydrolysis of PC than the mammalian group II enzyme (11). In addition, mRNA for a group X enzyme has been isolated from human lung tissue, but activity of this enzyme against PC or other surfactant-associated phospholipids is unknown (10). Studies similar to those reported here are needed to define the role for those secretory phospholipases A2 in surfactant dysfunction.

There are variations and uncertainties in the functional activity of native and recombinant group II enzymes that make it impossible to conclude that all group II enzymes cannot contribute to the hydrolysis of surfactant-associated PC. Both group II secretory phospholipases A2 (rhGpII and HuSF) demonstrated excellent activity on the bacterial substrate E. coli, which suggests that the intact protein with proper folding was present. Various compounds can serve to modify activation of secretory phospholipases A2, including the inhibitory low-molecular-weight Clara cell protein (23), and could therefore impact our results if present. The similarity in our results for the hydrolysis of NPS and Survanta, which is commercially purified and prepared, suggests that contaminating inhibitors like the Clara cell protein were not a factor in our experiments. In addition, our studies do not exclude that higher rates of hydrolysis for the labeled surfactant might not be seen if higher concentrations of rhGpII sPLA2 (>10,000 U/ml) were used. Our comparisons of group I and II activities are based on the relative activity of each toward E. coli as a substrate and not the absolute levels of enzyme in surfactant. If levels of group II sPLA2 within the inflamed alveolar microenvironment in ARDS or asthma increased beyond those used in this study, significant hydrolysis could occur.

There are also important variables in the physical state of the substrate of sPLA2-mediated hydrolysis that may have contributed to our results. The group I secretory phospholipases A2 have a higher affinity for PC than group II secretory phospholipases A2 and might be expected to demonstrate the results we have shown. Group II secretory phospholipases A2 preferentially hydrolyze phosphatidylethanolamine and phosphatidylglycerol as substrates (20, 38). We did not examine the ability of the group I or II enzymes to hydrolyze surfactant-associated phospholipids other than PC. In our experimental incubations, the air-liquid interface at the top of the microcentrifuge tube was small. As a result, the greatest percentage of the phospholipid was not in a monomolecular film but more likely in vesicles. We cannot exclude the possibility that the group II sPLA2 could more readily hydrolyze surfactant-associated PC in a monomolecular film as found in the alveolus. Another potential variable within the surfactant mixture that could lead to altered presentation of the substrate to the enzyme is the SPs. The similar activity of group I and II secretory phospholipases A2 on NPS and Survanta suggests that SP-A and -D, which are not present in Survanta, play little or no role in determining enzymatic activity. Low levels of SP-B and -C are present in Survanta, and, therefore, we cannot evaluate their role in regulation of sPLA2-mediated hydrolysis.

The mechanism of phospholipase-induced dysfunction of surfactant is likely to be multifactorial. Because the enzymatic reaction results in a reduction in the native phospholipids and an increase in lysophospholipids and free fatty acids, both have been shown to inhibit in vitro surface tension lowering of surfactant activity (9, 18). Any one of these changes in the surrounding milieu of the alveolar monolayer and subphase could potentially interfere with the ability of the surfactant layer to pack tightly, associate with the SPs, and subsequently lower gamma . In all likelihood, it is a combination of these events that explains the subsequent dysfunction, and clarification of this intricate relationship warrants further investigation. From the data in Fig. 6, it is intriguing to note the sharp contrast in function shown between 100 and 500 U/ml of the group I pancreatic enzyme despite hydrolysis steadily increasing within the same concentration range. These data suggest that there may be a critical concentration or relationship between the ratio of intact phospholipids, lysophospholipids, and fatty acids that determines the function of the surfactant film.

In summary, our data demonstrate that there are significant differences between the mammalian group I and group II secretory phospholipases A2 and their ability to hydrolyze surfactant-associated PC and lead to surfactant dysfunction. These findings have important implications in the role of sPLA2 in inflammatory lung conditions like ARDS and asthma.

    ACKNOWLEDGEMENTS

We gratefully acknowledge the generosity of Dr. Robert Dillard (Department of Pediatrics/Neonatology, Wake Forest University School of Medicine, Winston-Salem, NC) for providing Survanta samples and Dr. Lisa Marshall (Smith Kline Beecham, King of Prussia, PA) for providing the cDNA that was utilized for our recombinant human group II sPLA2 gene construct.

    FOOTNOTES

Fatty acid analyses were performed by the Analytic Chemistry Laboratory of the Comprehensive Cancer Center of Wake Forest University, supported in part by National Cancer Institute Grant CA-12107. This work was supported in part by National Heart, Lung, and Blood Institute Grant P01-HL-50395.

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Address for reprint requests: R. D. Hite, Section on Pulmonary and Critical Care Medicine, Wake Forest Univ. School of Medicine, Winston-Salem, NC 27157.

Received 29 January 1998; accepted in final form 29 May 1998.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

1.   Balboa, M. A., J. Balsinde, M. V. Winstead, J. A. Tischfield, and E. A. Dennis. Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages. J. Biol. Chem. 271: 32381-32384, 1996[Abstract/Free Full Text].

2.   Bartlett, G. B. Phosphorus assay in column chromatography. J. Biol. Chem. 234: 466-468, 1959[Free Full Text].

3.  Bass, D. A., M. C. Seeds, D. F. Jones, F. H. Chilton, and S. A. Bauldry. Priming of phospholipases A2 of human neutrophils by tumor necrosis factor. Chest 105, Suppl.: 99S-100S, 1994.

4.   Bligh, E. G., and W. J. Dyer. A rapid method for total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917, 1959.

5.   Bowton, D. L., M. C. Seeds, M. B. Fasano, B. Goldsmith, and D. A. Bass. Phospholipase A2 and arachidonate increase in bronchoalveolar lavage fluid after inhaled antigen challenge in asthmatics. Am. J. Respir. Crit. Care Med. 155: 421-425, 1997[Abstract].

6.   Chang, H. W., I. Kudo, M. Tomita, and K. Inoue. Purification and characterization of extracellular phospholipase A2 from peritoneal cavity of caseinate-treated rat. J. Biochem. (Tokyo) 102: 147-154, 1987[Abstract].

7.   Chilton, F. H., F. J. Averill, W. C. Hubbard, A. N. Fonteh, M. Triggiani, and M. Liu. Antigen-induced generation of lyso-phospholipids in human airways. J. Exp. Med. 183: 2235-2245, 1996[Abstract].

8.   Clark, J. D., N. Milona, and J. L. Knopf. Purification of a 110-kilodalton cytosolic phospholipase A2 from the human monocytic cell line U937. Proc. Natl. Acad. Sci. USA 87: 7708-7712, 1990[Abstract].

9.   Cockshutt, A. M., and F. Possmayer. Lysophosphatidylcholine sensitizes lipid extracts of pulmonary surfactant to inhibition by serum proteins. Biochim. Biophys. Acta 1086: 63-71, 1991[Medline].

10.   Cupillard, L., K. Koumanov, M. G. Mattei, M. Lazdunski, and G. Lambeau. Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2. J. Biol. Chem. 272: 15745-15752, 1997[Abstract/Free Full Text].

11.   Dennis, E. A. The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem. Sci. 22: 1-2, 1997[Medline].

12.   Dobbs, L. G. Pulmonary surfactant. Annu. Rev. Med. 40: 431-446, 1989[Medline].

13.   Edelson, J. D., P. Vadas, J. Villar, J. B. Mullen, and W. Pruzanski. Acute lung injury induced by phospholipase A2. Structural and functional changes. Am. Rev. Respir. Dis. 143: 1102-1109, 1991[Medline].

14.   Enhorning, G. Pulsating bubble technique for evaluating pulmonary surfactant. J. Appl. Physiol. 43: 198-203, 1977[Abstract/Free Full Text].

15.   Fine, J. B., and H. Sprecher. Unidimensional thin-layer chromatography of phospholipids on boric acid-impregnated plates. J. Lipid Res. 23: 660-663, 1982[Abstract].

16.   Gregory, T. J., W. J. Longmore, M. A. Moxley, J. A. Whitsett, C. R. Reed, A. A. Fowler, L. D. Hudson, R. J. Maunder, C. Crim, and T. M. Hyers. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J. Clin. Invest. 88: 1976-1981, 1991[Medline].

17.   Gronroos, J. M., K. Kuttila, and T. J. Nevalainen. Group II phospholipase A2 in serum in critically ill surgical patients. Crit. Care Med. 22: 956-959, 1994[Medline].

18.   Hall, S. B., R. Z. Lu, A. R. Venkitaraman, R. W. Hyde, and R. H. Notter. Inhibition of pulmonary surfactant by oleic acid: mechanisms and characteristics. J. Appl. Physiol. 72: 1708-1716, 1992[Abstract/Free Full Text].

19.   Hallman, M., R. Spragg, J. H. Harrell, K. M. Moser, and L. Gluck. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J. Clin. Invest. 70: 673-683, 1982[Medline].

20.   Hara, S., I. Kudo, H. W. Chang, K. Matsuta, T. Miyamoto, and K. Inoue. Purification and characterization of extracellular phospholipase A2 from human synovial fluid in rheumatoid arthritis. J. Biochem. (Tokyo) 105: 395-399, 1989[Abstract].

21.   Hohlfeld, J., H. Fabel, and H. Hamm. The role of pulmonary surfactant in obstructive airways disease. Eur. J. Respir. Dis. 10: 482-491, 1997.

22.   Holm, B. A., L. Keicher, M. Y. Liu, J. Sokolowski, and G. Enhorning. Inhibition of pulmonary surfactant function by phospholipases. J. Appl. Physiol. 71: 317-321, 1991[Abstract/Free Full Text].

23.   Jorens, P. G., Y. Sibille, N. J. Goulding, F. J. van Overveld, A. G. Herman, L. Bossaert, W. A. De Backer, R. Lauwerys, R. J. Flower, and A. Bernard. Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury. Eur. Respir. J. 8: 1647-1653, 1995[Abstract/Free Full Text].

24.   Kahn, M. C., G. J. Anderson, W. R. Anyan, and S. B. Hall. Phosphatidylcholine molecular species of calf lung surfactant. Am. J. Physiol. 269 (Lung Cell. Mol. Physiol. 13): L567-L573, 1995[Abstract/Free Full Text].

25.   Kim, D. K., T. Fukuda, B. T. Thompson, B. Cockrill, C. Hales, and J. V. Bonventre. Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome. Am. J. Physiol. 269 (Lung Cell. Mol. Physiol. 13): L109-L118, 1995[Abstract/Free Full Text].

26.   Kramer, R. M., and R. B. Pepinsky. Assay and purification of phospholipase A2 from human synovial fluid in rheumatoid arthritis. Methods Enzymol. 197: 373-381, 1991[Medline].

27.   Kuroki, Y., and D. R. Voelker. Pulmonary surfactant proteins. J. Biol. Chem. 269: 25943-25946, 1996[Free Full Text].

28.  Lewis, J. F., and R. A. Veldhuizen. Factors influencing efficacy of exogenous surfactant in acute lung injury. Biol. Neonate 7, Suppl. 1: 48-60, 1995.

29.   Liu, M., L. Wang, and G. Enhorning. Surfactant dysfunction develops when the immunized guinea-pig is challenged with ovalbumin aerosol. Clin. Exp. Allergy 25: 1053-1060, 1995[Medline].

30.   Rae, D., J. Porter, N. Beechey-Newman, N. Sumar, D. Bennett, and J. Hermon-Taylor. Type 1 prophospholipase A2 propeptide in acute lung injury. Lancet 344: 1472-1473, 1994[Medline].

31.   Rae, D., N. Sumar, N. Beechey-Newman, M. Gudgeon, and J. Hermon-Taylor. Type 1-prophospholipase A2 propeptide immunoreactivity is released from activated granulocytes. Clin. Biochem. 28: 71-78, 1995[Medline].

32.   Robertson, B. Neonatal respiratory distress syndrome and surfactant therapy; a brief review. Eur. Respir. J. Suppl. 3: 73S-76S, 1989[Medline].

33.   Rogozinski, M. A rapid quantitative esterification technique for carboxylic acids. J. Gas Chromatogr. 2: 328-329, 1964.

34.   Schroder, T., M. Lempinen, E. Kivilaakso, and P. Nikki. Serum phospholipase A2 and pulmonary changes in acute fulminant pancreatitis. Resuscitation 10: 79-87, 1982[Medline].

35.   Seilhamer, J. J., T. L. Randall, M. Yamanaka, and L. K. Johnson. Pancreatic phospholipase A2: isolation of the human gene and cDNAs from porcine pancreas and human lung. DNA (NY) 5: 519-527, 1986[Medline].

36.   Vadas, P., J. Browning, J. Edelson, and W. Pruzanski. Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J. Lipid Mediators 8: 1-30, 1993[Medline].

37.   VanDeenen, L. L. M., and G. H. DeHaas. The substrate specificity of phospholipase A. Biochim. Biophys. Acta 70: 538-553, 1963.

38.   Verger, R., F. Ferrato, C. M. Mansbach, and G. Pieroni. Novel intestinal phospholipase A2: purification and some molecular characteristics. Biochemistry 21: 6883-6889, 1982[Medline].

39.   Verheij, H. M., J. Westerman, B. Sternby, and G. H. de Haas. The complete primary structure of phospholipase A2 from human pancreas. Biochim. Biophys. Acta 747: 93-99, 1983[Medline].

40.   Vial, D., M. Senorale-Pose, N. Havet, L. Molio, B. B. Vargaftig, and L. Touqui. Expression of the type-II phospholipase A2 in alveolar macrophages. Down-regulation by an inflammatory signal. J. Biol. Chem. 270: 17327-17332, 1995[Abstract/Free Full Text].

41.   Waite, M. Phospholipases, enzymes that share a substrate class. Adv. Exp. Med. Biol. 279: 1-22, 1990[Medline].

42.   Weiss, J., M. Inada, P. Elsbach, and R. M. Crowl. Structural determinants of the action against Escherichia coli of a human inflammatory fluid phospholipase A2 in concert with polymorphonuclear leukocytes. J. Biol. Chem. 269: 26331-26337, 1994[Abstract/Free Full Text].

43.   Wong, M. H., P. Oelkers, A. L. Craddock, and P. A. Dawson. Expression cloning and characterization of the hamster ileal sodium-dependent bile acid transporter. J. Biol. Chem. 269: 1340-1347, 1994[Abstract/Free Full Text].

44.   Yu, S. H., and F. Possmayer. Role of bovine pulmonary surfactant-associated proteins in the surface-active property of phospholipid mixtures. Biochim. Biophys. Acta 1046: 233-241, 1990[Medline].


Am J Physiol Lung Cell Mol Physiol 275(4):L740-L747
0002-9513/98 $5.00 Copyright © 1998 the American Physiological Society